Aug 8, 2017

Q2 2017 Earnings Conference Call

In This Section

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Recent Press Releases

Events & Presentations

Aug 8, 2017 at 8:30 AM
Mar 15, 2017 at 8:30 AM ET